Ziltivekimab
Based on 1 Customer Validation
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.75%
- CAS No.: 2226654-05-1
- Masse moléculaire:145.39 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-6 |
In Vitro
Ziltivekimab significantly reduces inflammatory biomarkers in chronic kidney disease patients with systemic inflammation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
Chemical Information
-
CAS No. 2226654-05-1
-
Appearance Liquid
-
Masse moléculaire 145.39 kDa
-
Color Colorless to light yellow
-
SMILES
[Ziltivekimab]
-
Synonyms
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. [Content Brief]
[2]. Pergola PE, et al. Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024;35(1):74-84. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ziltivekimab
- 2226654-05-1
- COR-001
- MEDI-5117
- NN-6018
- WBP-216
- COR001
- COR 001
- MEDI5117
- MEDI 5117
- MEDI-5117
- NN6018
- NN 6018
- NN-6018
- WBP216
- WBP 216
- WBP-216
- Interleukin Related
- LDLR
- high-sensitivity C-reactive protein
- chronic kidney disease
- atherothrombotic disease
- secretory phospholipase A2
- systemic inflammation
- lipoprotein(a)
- fibrinogen
- haptoglobin
- serum amyloid A
- IL-6 ligand
- Inhibitor
- inhibitor
- inhibit